Aclaris Says ATI-052 Had No Grade 3 or 4 Adverse Events
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Shenzhen Longsys Electronics Reports Quarterly Revenue of RMB 14.63 Billion
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
SUMMI Group Delays FY26 Annual Results Publication
SUMMI Group’s FY26 annual results publication is delayed due to audit procedures.
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
Shenzhen Longsys Electronics Reports Quarterly Net Profit of RMB 3.74 Billion
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
Insperity Shares Fall More Than 13% After Q3 Results and Updated Guidance
Insperity shares fell more than 13% after the company reported third-quarter results and updated its 2026 adjusted earnings guidance.
M impact | EQUITY | Oct 29, 2026, 02:38 PM UTC
Novavax Earns $125 Million Milestone Payment From Sanofi Vaccine Trial
Novavax earned a $125 million milestone payment from Sanofi's Phase 3 vaccine trial in Europe.
M impact | EQUITY | Oct 29, 2026, 02:38 PM UTC
Donnelley Financial Solutions Reports Higher Q3 Adjusted Earnings and Net Sales
Donnelley Financial Solutions reported higher adjusted earnings and net sales in Q3.
M impact | EQUITY | Oct 29, 2026, 02:38 PM UTC